Dialysis clinic operator DaVita (DVA +3.1%) signs a new, seven-year agreement to receive Amgen's (AMGN -0.5%) anti-anemia drug Epogen. In an SEC filing, Amgen discloses that the Epogen it supplies will meet at least 90% of DaVita's requirements for erythropoiesis stimulating agents in clinics in the U.S. and Puerto Rico.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Dec 23, 2014)
at Nasdaq.com (Nov 19, 2014)
at CNBC.com (Nov 7, 2014)
at MarketWatch.com (Aug 26, 2014)
at MarketWatch.com (Jul 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs